Loading clinical trials...
Loading clinical trials...
This extension study was to monitor the long-term safety and efficacy of rhGAA treatment in patients with infantile-onset Pompe disease who were previously treated with rhGAA derived from the Synpac c...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Genzyme, a Sanofi Company
NCT06666413 · Glycogen Storage Disease Type II, Pompe's Disease
NCT07136844 · Neuromuscular Diseases, Obesity (Disorder), and more
NCT06616545 · Glycogen Storage Disease Type III
NCT04093349 · Pompe Disease, Pompe Disease (Late-onset), and more
NCT04990388 · Glycogen Storage Disease Type III
Children's Hospital of Oakland
Oakland, California
Children's Hospital of Orange Country
Orange, California
University of Nebraska Medical Center
Omaha, Nebraska
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions